Evidence map›Paper›PMID 34681731›Full record

ArticleInternational journal of molecular sciences2021

Mass Spectrometry-Based Proteomics Reveal Alcohol Dehydrogenase 1B as a Blood Biomarker Candidate to Monitor Acetaminophen-Induced Liver Injury.

Floriane Pailleux, Pauline Maes, Michel Jaquinod, Justine Barthelon, Marion Darnaud, Claire Lacoste, Yves Vandenbrouck, Benoît Gilquin, Mathilde Louwagie, Anne-Marie Hesse and 10 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Floriane PailleuxUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.
Pauline MaesUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.
Michel JaquinodUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.
Justine BarthelonUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.
Marion DarnaudHepatobiliary Centre, Paul-Brousse University Hospital, INSERM U1193, 94800 Villejuif, France.ORCID 0000-0002-0919-8303
Claire LacosteHepatobiliary Centre, Paul-Brousse University Hospital, INSERM U1193, 94800 Villejuif, France.ORCID 0000-0001-7013-2533
Yves VandenbrouckUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.ORCID 0000-0002-1292-373X
Benoît GilquinUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.ORCID 0000-0001-8138-7021
Mathilde LouwagieUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.
Anne-Marie HesseUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.ORCID 0000-0001-6110-0636
Alexandra KrautUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.
Jérôme GarinUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.
Vincent LeroyClinique Universitaire d'Hépato-gastroentérologie, Centre Hospitalier Universitaire Grenoble, 38000 Grenoble, France.
Jean-Pierre ZarskiClinique Universitaire d'Hépato-gastroentérologie, Centre Hospitalier Universitaire Grenoble, 38000 Grenoble, France.
Christophe BruleyUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.
Yohann CoutéUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.ORCID 0000-0003-3896-6196
Didier SamuelHepatobiliary Centre, Paul-Brousse University Hospital, INSERM U1193, 94800 Villejuif, France.
Philippe IchaiHepatobiliary Centre, Paul-Brousse University Hospital, INSERM U1193, 94800 Villejuif, France.
Jamila FaivreHepatobiliary Centre, Paul-Brousse University Hospital, INSERM U1193, 94800 Villejuif, France.
Virginie BrunUniv. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048, 38000 Grenoble, France.ORCID 0000-0002-9098-8707
Centre National de la Recherche Scientifique · FRUniversité Paris-Sud · FR

Funding

Chemistry Biology Health Graduate School of University Grenoble Alpes ANR-17-EURE-0003French National Research Agency ANR, LIFE project ANR-15-IDEX-02Investissement d'Avenir Infrastructures Nationales en Biologie et Santé, ProFI project ANR-10-INBS-08
6 · The paper itself

Abstract

Acute liver injury (ALI) is a severe disorder resulting from excessive hepatocyte cell death, and frequently caused by acetaminophen intoxication. Clinical management of ALI progression is hampered by the dearth of blood biomarkers available. In this study, a bioinformatics workflow was developed to screen omics databases and identify potential biomarkers for hepatocyte cell death. Then, discovery proteomics was harnessed to select from among these candidates those that were specifically detected in the blood of acetaminophen-induced ALI patients. Among these candidates, the isoenzyme alcohol dehydrogenase 1B (ADH1B) was massively leaked into the blood. To evaluate ADH1B, we developed a targeted proteomics assay and quantified ADH1B in serum samples collected at different times from 17 patients admitted for acetaminophen-induced ALI. Serum ADH1B concentrations increased markedly during the acute phase of the disease, and dropped to undetectable levels during recovery. In contrast to alanine aminotransferase activity, the rapid drop in circulating ADH1B concentrations was followed by an improvement in the international normalized ratio (INR) within 10-48 h, and was associated with favorable outcomes. In conclusion, the combination of omics data exploration and proteomics revealed ADH1B as a new blood biomarker candidate that could be useful for the monitoring of acetaminophen-induced ALI.

Indexed as

AcetaminophenAlcohol DehydrogenaseBiomarkersChemical and Drug Induced Liver InjuryChromatography, High Pressure LiquidComputational BiologyHumansInternational Normalized RatioLimit of DetectionProteomicsTandem Mass SpectrometryAcetaminophenADH1B protein, humanAlcohol DehydrogenaseBiomarkersacetaminophenbioinformaticsbiomarkerbloodlivermass spectrometryproteomics

Identifiers

PMID34681731
PMCPMC8540689
OpenAlexW3205511259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.